Patient Guide: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 213 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT04191096
Status: ACTIVE_NOT_RECRUITING
Condition: Metastatic Hormone-Sensitive Prostate Cancer
Phase: PHASE3

Where You Can Participate

This study is available at 213 locations across the country.

Top locations include:
  • • Anchorage, Alaska
  • • Anchorage, Alaska
  • • Duarte, California
  • • And 210 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) - Join Clinical Trial NCTNCT04191096

How to Join This Clinical Trial - NCTNCT04191096

Learn how to participate in this PHASE3 trial studying an investigational therapy for Metastatic Hormone-Sensitive Prostate Cancer. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Metastatic Hormone-Sensitive Prostate Cancer. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Metastatic Hormone-Sensitive Prostate Cancer
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT04191096 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 213 locations. Find a study site near you:

Clinical Research Site

Anchorage, Alaska 99503 - United States

Status: Contact for availability

Clinical Research Site

Anchorage, Alaska 99508 - United States

Status: Contact for availability

Clinical Research Site

Duarte, California 91010 - United States

Status: Contact for availability

Clinical Research Site

Los Angeles, California 90404 - United States

Status: Contact for availability

Clinical Research Site

Aurora, Colorado 80045 - United States

Status: Contact for availability

Clinical Research Site

Manchester, Connecticut 06042 - United States

Status: Contact for availability

Clinical Research Site

New Haven, Connecticut 06510 - United States

Status: Contact for availability

Clinical Research Site

Washington, District of Columbia 20016 - United States

Status: Contact for availability

Clinical Research Site

Atlanta, Georgia 30322-1013 - United States

Status: Contact for availability

Clinical Research Site

Chicago, Illinois 60637 - United States

Status: Contact for availability

And 203 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Metastatic Hormone-Sensitive Prostate Cancer:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships